Increase efficiencies and productivity by automating core reporting tasks for medical writing.
Automate core regulatory report documents across the CTD pyramid and dramatically accelerate submission timelines.
Increase efficiencies and productivity by automating core reporting tasks for medical writing.
Automate core regulatory report documents across the CTD pyramid and dramatically accelerate submission timelines.
New York, June 16, 2026 — Yseop has been recognized in Fast Company’s 2026 World Changing Ideas Awards for helping life sciences organizations transform regulatory writing through AI, streamlining one of the most critical stages of the drug development process.
Now in its ninth year, the World Changing Ideas Awards recognize organizations and projects delivering measurable impact across industries, from healthcare and climate to education, social impact, and beyond. This year’s honorees were selected from more than 1,500 entries by a panel of Fast Company editors and reporters and evaluated on impact, creativity, scalability, sustainability, and their potential to improve society.
Yseop was recognized for its regulatory AI platform, which combines neuro-symbolic AI and large language models to automate the creation of complex regulatory documents. By reducing manual effort while maintaining the accuracy, traceability, and compliance required by global health authorities, Yseop helps life sciences teams accelerate the journey from scientific innovation to patient access.
“The World Changing Ideas Awards are more than inspiration — they’re a measure of real-world impact,” said Fast Company Editor-in-Chief Brendan Vaughan. “This year’s honorees are turning bold ideas into tangible solutions and addressing urgent global challenges with creativity and rigor.”
“This recognition reflects the growing importance of modernizing regulatory workflows across the life sciences industry,” said Elizabeth Curtin, VP of Marketing at Yseop. “We’re proud to help organizations accelerate the development and delivery of new therapies while maintaining the high standards of quality and compliance that patients and regulators depend on.”
As AI becomes increasingly central to life sciences operations, Yseop remains focused on helping regulatory teams adopt it in ways that are practical, compliant, and built for the complexity of real submissions.